WEBULL
News
DYN
15.54
-2.88%
-0.46
Weekly Report: what happened at DYN last week (0202-0206)?
Weekly Report · 5d ago
Weekly Report: what happened at DYN last week (0126-0130)?
Weekly Report · 02/02 10:29
Dyne Therapeutics: 2026 Catalysts Point To Further Upside
Seeking Alpha · 01/27 09:07
Weekly Report: what happened at DYN last week (0119-0123)?
Weekly Report · 01/26 10:29
Dyne Therapeutics (DYN) Is Up 7.8% After Japan Grants Orphan Status To DM1 Drug Candidate
Simply Wall St · 01/24 08:32
ClearBridge Small-Cap Growth trims Duolingo, Biohaven, QLYS; Adds PTGX, SSD, BETA, DYN in Q4
Seeking Alpha · 01/22 14:53
Analysts Offer Insights on Healthcare Companies: Monopar Therapeutics Inc (MNPR) and Dyne Therapeutics (DYN)
TipRanks · 01/21 14:50
Dyne Therapeutics Price Target Cut to $16.00/Share From $17.00 by JP Morgan
Dow Jones · 01/20 15:26
Dyne Therapeutics Is Maintained at Neutral by JP Morgan
Dow Jones · 01/20 15:26
JP Morgan Maintains Neutral on Dyne Therapeutics, Lowers Price Target to $16
Benzinga · 01/20 15:15
Dyne Therapeutics Announces Orphan Drug Designation For Z-basivarsen In Japan
NASDAQ · 01/20 12:51
Dyne announces MHLW in Japan granted ODD for zeleciment basivarsen
TipRanks · 01/20 12:36
Dyne Therapeutics Announces MHLW In Japan Grants Orphan Drug Designation For Zeleciment Basivarsen For Treatment Of Myotonic Muscular Dystrophy Type 1
Benzinga · 01/20 12:31
Japan Grants Orphan Drug Designation to Dyne Therapeutics' Zeleciment Basivarsen for Myotonic Dystrophy Type 1
Reuters · 01/20 12:30
DYNE THERAPEUTICS INC - ACHIEVE TRIAL ENROLLMENT EXPECTED TO COMPLETE EARLY Q2 2026
Reuters · 01/20 12:30
DYNE THERAPEUTICS INC <DYN.O>: JP MORGAN CUTS TARGET PRICE TO $16 FROM $17
Reuters · 01/20 05:22
Weekly Report: what happened at DYN last week (0112-0116)?
Weekly Report · 01/19 10:35
A Look At Dyne Therapeutics (DYN) Valuation As Strong Buy Ratings Follow Neuromuscular Program Updates
Simply Wall St · 01/17 22:18
Is Dyne Therapeutics' (DYN) Late-Stage DMD Progress Redefining Its Rare Disease Investment Story?
Simply Wall St · 01/15 17:24
Funding for Risky Biotechs Is Returning
The Wall Street Journal · 01/12 17:00
More
Webull provides a variety of real-time DYN stock news. You can receive the latest news about Dyne Therapeutics, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About DYN
Dyne Therapeutics, Inc. is a clinical-stage neuromuscular disease company. It is discovering and advancing therapeutics for people living with genetically driven neuromuscular diseases. Leveraging the modularity of its FORCE platform, it is developing targeted therapeutics that deliver to muscle and the central nervous system (CNS). It has a broad pipeline for neuromuscular diseases, including clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD) and preclinical programs for facioscapulohumeral muscular dystrophy (FSHD) and Pompe disease. Its product candidate, DYNE-101, is being evaluated in ACHIEVE, an ongoing Phase I/II global clinical trial in patients with DM1. Its product candidate, DYNE-251, is being evaluated in DELIVER, an ongoing Phase I/II global clinical trial in patients with DMD who have mutations amenable to exon 51 skipping. Its other product candidates are DYNE-302 and DYNE-401. DYNE-302 addresses the genetic basis of FSHD.